Roche has reported that Polivy (polatuzumab vedotin) plus chemotherapy regimen met the primary goal of Phase III POLARIX clinical trial for treatment naïve diffuse large B-cell lymphoma (DLBCL).

The chemotherapy regimen included MabThera/Rituxan (rituximab) along with cyclophosphamide, doxorubicin and prednisone (R-CHP).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Polivy is an anti-CD79b antibody-drug conjugate (ADC) being developed by Roche using the ADC technology of Seagen.

The ADC attaches to cancer cells such as CD79b and destroys these B-cells by delivering an anti-cancer agent, which is believed to reduce the effects on normal cells.

The global, randomised, double-blind, placebo-controlled Phase III POLARIX trial analysed the efficacy, safety and pharmacokinetics of Polivy plus R-CHP compared with standard of care (SoC) treatment in 879 DLBCL patients.

The SoC regimen included MabThera/Rituxan, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP).

Trial data showed that Polivy plus R-CHP offered substantial improvement and clinically meaningful progression-free survival (PFS), meeting the primary goal.

Furthermore, the safety profile of the drug was in line with that observed in earlier trials.

Polivy plus R-CHP is the first treatment in two decades to boost outcomes in a previously untreated aggressive form of lymphoma, Roche noted.

Roche chief medical officer and Global Product Development head Levi Garraway said: “Since 40% of people with DLBCL relapse after initial therapy, achieving meaningful treatment effects in the front-line setting has the potential to be transformative.

“This Polivy regimen is the first in two decades to improve progression-free survival in DLBCL compared to the standard of care, and we look forward to sharing these results with health authorities to bring this important potential new treatment option to patients as soon as possible.”

The company added that the data from the POLARIX trial will be submitted to health authorities across the world soon.

Polivy is currently approved for use, along with bendamustine and MabThera/Rituxan, for relapsed or refractory DLBCL treatment in more than 60 countries, including the US and EU.

Last month, Roche reported that Evrysdi (risdiplam) met the primary goal of the FIREFISH Part 2 study in infants aged one to seven months with symptomatic Type 1 spinal muscular atrophy (SMA).